David van Duin

65PUBLICATIONS
154CO-AUTHORS
Planning and decision makingPharmacogenomicsMedical bacteriologyMajor global burdens of diseaseMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (65)

|Aug 04, 2026
Development and Application of an Anaerobic Activity Index.

|May 15, 2026
Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas study.

|Apr 30, 2026
Sulbactam-durlobactam and cefiderocol combination treatment of Burkholderia cenocepacia-associated Fitz-Hugh-Curtis syndrome.

|Apr 27, 2026
Difficult-to-treat resistance (DTR), treatment, and outcomes of carbapenem-resistant Enterobacterales infections in the setting of IMP-type carbapenemase predominance in Japan.

|Apr 08, 2026
A Val292 substitution combined with an alanine duplication (ADUP) in the Ω loop of ADC β-lactamase confers reduced susceptibility to advanced β-lactam agents, including cefiderocol.

Akito Kawai, Christi L McElheny, Ryan K Shields

|Mar 08, 2026
Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections.

Natalie A Mackow, Wanying Shao, Lizhao Ge

Pageof 11

Frequent Collaborators

14 joint publications

Robin Patel

14 joint publications

Yohei Doi

12 joint publications

Robert A Bonomo

6 joint publications

Liang Chen